Hoffmann-la Roche

This phase 3 trial tested alectinib against crizotinib in 187 Asian patients with advanced ALK-positive non-small cell lung cancer who had not received prior treatment. Patients took either alectinib or crizotinib capsules twice daily. The study found that alectinib significantly…

This study is testing the drug risdiplam in newborn babies with spinal muscular atrophy (SMA), a serious muscle-weakening disease. The goal is to see how the drug moves through the body and if it is safe for infants under 20 days old. Ten babies will take part, and researchers wi…

This study tested a fixed-dose combination of two immunotherapy drugs, tiragolumab and atezolizumab, given together as a single infusion every three weeks. The trial enrolled 64 people with advanced solid tumors that express a protein called PD-L1. The main goal was to check the …

This study tested whether a combination of two drugs (atezolizumab and bevacizumab) can prevent liver cancer from returning in people who had surgery or ablation to remove their tumor. About 668 participants at high risk of recurrence were randomly assigned to receive the drug co…

This study tests a drug called faricimab (VABYSMO) in people with diabetic macular edema, a condition where diabetes causes fluid buildup in the center of the retina, leading to vision loss. Participants receive injections of faricimab into the eye every four weeks. The goal is t…

This study offers ongoing treatment with alectinib or crizotinib to about 200 adults with ALK- or RET-positive cancer who were already benefiting from these drugs in a previous Roche trial. The main goal is to monitor safety and side effects as patients continue therapy after the…

This study tested a drug called faricimab (VABYSMO®) against an existing treatment (ranibizumab) for people with vision loss caused by abnormal blood vessels growing in the back of the eye due to severe nearsightedness. The trial involved 280 participants who received either fari…

This study tested whether adding the experimental immunotherapy tiragolumab to a standard combination of atezolizumab and chemotherapy works better than the current standard treatment (pembrolizumab plus chemotherapy) for people with advanced non-squamous non-small cell lung canc…

This phase 3 trial tested whether combining two immunotherapy drugs, atezolizumab and tiragolumab, works better than the standard drug durvalumab for people with stage III lung cancer that cannot be surgically removed. The 829 participants had already received chemotherapy and ra…

This phase 3 study tested alectinib against crizotinib in 303 people with advanced ALK-positive non-small cell lung cancer who had not received prior treatment. Participants took one of the two drugs twice daily until their cancer worsened or side effects became too severe. The m…

This phase 2 trial tested a new drug called vamikibart, given as an eye injection, for people with diabetic macular edema—a condition where diabetes causes fluid buildup in the center of the retina, leading to vision loss. The study involved 394 participants and compared vamikiba…

This large Phase 3 trial tested whether adding polatuzumab vedotin to standard chemotherapy (R-CHP) works better than the usual treatment (R-CHOP) for people with untreated diffuse large B-cell lymphoma. About 1000 participants received either the new combo or the standard regime…

This phase 2 trial tested whether adding tiragolumab to atezolizumab (Tecentriq) helps shrink tumors better than atezolizumab alone in people with advanced head and neck cancer that has come back or spread. The study enrolled 123 adults whose tumors have a specific protein (PD-L1…

This study tested an eye injection called vamikibart in 256 people with uveitic macular edema, a condition where swelling in the eye damages vision. Participants received either the drug or a sham procedure. The main goal was to see if vision improved by at least 15 letters on an…

This early-stage trial tested a new drug called forimtamig in 225 people with multiple myeloma that had returned or stopped responding to standard treatments. The main goals were to check safety and find the right dose. Participants received the drug by IV or injection, and resea…

This phase 3 trial tested whether adding two immunotherapy drugs, atezolizumab and tiragolumab, to standard chemotherapy could help people with advanced esophageal cancer live longer. About 461 participants received either the immunotherapy combo plus chemo or a placebo plus chem…

This phase 3 trial tested a small, refillable implant placed in the eye that continuously releases the drug ranibizumab to control diabetic retinopathy. The study enrolled 174 people with moderate-to-severe non-proliferative diabetic retinopathy but without swelling in the center…

This study tested whether adding a new drug called tiragolumab to standard chemotherapy and immunotherapy helps people with advanced small cell lung cancer live longer without their cancer getting worse. About 490 adults who had not received prior treatment for this stage of canc…

This phase 3 trial tested emicizumab (Hemlibra) in 85 people with hemophilia A, a condition where blood doesn't clot properly, causing frequent bleeds. Participants received either emicizumab injections or no preventive treatment. The study found that those on emicizumab had sign…

This phase 2 trial tested two experimental drugs, lomvastomig and tobemstomig, against the standard immunotherapy nivolumab in 190 people with advanced esophageal cancer that had worsened after chemotherapy. The drugs are bispecific antibodies designed to block two immune checkpo…

This study tested a new drug combination (tiragolumab plus atezolizumab) against atezolizumab alone in 172 people with advanced or returning cervical cancer that has a specific marker (PD-L1-positive). The goal was to see if the combination could shrink tumors better. Participant…

This phase 3 study tested whether a combination of two targeted drugs, venetoclax and obinutuzumab, works better than standard chemotherapy (FCR or BR) in 166 fit patients with previously untreated chronic lymphocytic leukemia (CLL) who lack certain genetic mutations. The main go…

This completed Phase 3 trial tested whether a fixed-dose combination of two targeted drugs (pertuzumab and trastuzumab) given as a simple shot under the skin works as well as the standard IV infusion in 200 Chinese patients with HER2-positive early breast cancer. The study measur…

This study followed 1,710 people with relapsing or primary progressive multiple sclerosis who were prescribed ocrelizumab (Ocrevus) as part of their normal care. Researchers tracked symptoms like fatigue, mobility, and cognition, as well as side effects, to see how well the drug …

This study looked at the long-term safety of faricimab, a medicine injected into the eye, for people with diabetic macular edema (DME). About 1,500 patients who had completed earlier studies received faricimab at personalized intervals. The main goal was to track side effects, no…

This study tested two different doses of an experimental drug called RO7247669 in 93 people with advanced melanoma that had not been treated before. The goal was to see how well the drug controls the cancer and to find the best dose with the fewest side effects. Participants rece…

This study tested whether adding a new drug called tiragolumab to the standard immunotherapy atezolizumab works better than atezolizumab alone for people with advanced non-small cell lung cancer that has not been treated before. About 620 participants with high levels of a protei…

This study tested a medicine called emicizumab in 73 people with mild or moderate hemophilia A who do not have inhibitors. The goal was to see if it safely reduces the number of bleeding episodes. Participants received regular injections, and the results showed fewer bleeds compa…

This study tested several immunotherapy-based drug combinations in 272 people with advanced bladder cancer that had worsened after platinum chemotherapy. The goal was to see which combinations were safest and most effective at shrinking tumors or slowing the disease. Participants…

This study tested whether adding the immunotherapy drug atezolizumab to standard chemotherapy before surgery helps people with stage II to IIIB non-small cell lung cancer live longer without the cancer coming back. About 453 participants received either atezolizumab plus chemo or…

This study tested the safety of combining the immunotherapy drug atezolizumab with the chemotherapy nab-paclitaxel in 184 people with advanced triple-negative breast cancer that had spread. Participants had not received prior chemotherapy for their advanced disease. The main goal…

This study tested whether combining the immunotherapy atezolizumab (Tecentriq) with the targeted drug cabozantinib works better than the standard chemotherapy docetaxel for people with advanced non-small cell lung cancer that has worsened after prior treatment. The trial enrolled…

This Phase 3 trial tested whether adding the targeted drug polatuzumab vedotin to standard chemotherapy (R-GEMOX) helps people with relapsed or refractory diffuse large B-cell lymphoma. The study involved 270 participants and compared the combination to chemotherapy alone. The ma…

This early-phase study tested a new drug called RO7623066, given alone or with other treatments, in 116 adults with advanced solid tumors that had not responded to prior therapies. The main goals were to find the safest dose and check for side effects. While not a cure, the study…

This study tested a drug called TRO19622 in 22 adults with NASH, a type of fatty liver disease. Participants took the drug or a placebo for one month to see if it improved liver enzyme levels and was safe. The goal was to gather early information on whether the drug might help co…

This study tested a new drug called PF-06480605 in 246 adults with moderate to severe ulcerative colitis. Participants received different doses of the drug or a placebo for 12 weeks, then everyone received the active drug for 40 more weeks. The goal was to see if the drug could h…

This study tested several immunotherapy-based drug combinations in 214 people with advanced stomach, gastroesophageal junction, or esophageal cancer that could not be removed by surgery or had spread. Participants received either standard chemotherapy or chemotherapy plus the imm…

This study tested giving immunotherapy drugs before surgery to people with liver cancer that could be removed. The goal was to see if these drug combinations could shrink the tumor or eliminate it before the operation. 62 participants took part in this early-phase trial, which ha…

This study tested whether a subcutaneous (under-the-skin) injection of the immunotherapy drug atezolizumab works as well as the standard intravenous (IV) infusion in people with advanced non-small cell lung cancer who had already tried platinum-based chemotherapy. The trial enrol…

This study tested a drug called alogabat in 48 children aged 5-17 with Angelman syndrome (a specific genetic type). The goal was to see how the drug moves through the body and if it is safe. Researchers also looked at brain activity changes to see if the drug works as expected. T…

This early-phase study tested a new drug, glofitamab, combined with standard chemotherapy (R-ICE) in 43 people with diffuse large B-cell lymphoma that returned or didn't respond to first treatment. Participants were eligible for a stem cell transplant or CAR-T therapy. The goal w…

This study tested whether adding the drug pertuzumab to standard chemotherapy and trastuzumab could help prevent breast cancer from returning after surgery. About 4,800 people with HER2-positive breast cancer took part. The results showed that the three-drug combination improved …

This study tested several immunotherapy-based drug combinations in 341 people with metastatic pancreatic cancer. Participants were split into two groups: those who had not yet received treatment and those who had already tried one type of chemotherapy. The goal was to see if thes…

This study tested an experimental drug called vamikibart, given as an eye injection, for people with uveitic macular edema — swelling in the back of the eye caused by inflammation. 245 adults with this condition took part. The main goal was to see if the drug improves vision by a…

This study tested whether using a person's tumor genetic profile to choose treatment works better than standard chemotherapy for cancer of unknown primary (CUP). About 529 adults whose cancer was controlled after initial chemo were randomly assigned to either gene-guided therapy …

This study followed over 1,000 people with multiple sclerosis who had already taken ocrelizumab in earlier trials. Participants received a 600-mg infusion every 24 months for two years. Researchers tracked disability progression, relapse rates, and safety to see if the drug remai…

This phase 3 trial tested whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps people with triple-negative breast cancer that has returned within 12 months of initial treatment. The study enrolled 595 participants and compared survival outcomes betwee…

This study tested several immunotherapy-based drug combinations in 144 people with advanced hormone receptor-positive, HER2-negative breast cancer that had worsened after initial treatment. Participants received atezolizumab (Tecentriq) along with other drugs like bevacizumab or …

This Phase 3 trial tested a combination of obinutuzumab and venetoclax against obinutuzumab plus chlorambucil in 445 people with untreated chronic lymphocytic leukemia (CLL) who also had other medical conditions. The goal was to see which combo worked better at delaying disease p…

This study looked at the long-term safety of faricimab, a drug injected into the eye, for people with wet age-related macular degeneration (AMD). Over 1,000 participants who had completed earlier studies received faricimab at personalized intervals. The main goal was to track sid…

This Phase II trial tested whether adding vamikibart to the standard treatment ranibizumab improves vision more than ranibizumab alone in people with diabetic macular edema. 187 participants received injections into the eye over 76 weeks. The study is complete, and results will s…

This study looked at 178 Chinese patients with HER2-positive advanced breast cancer who received the drug T-DM1 after earlier treatments failed. Researchers tracked side effects and how long the drug kept the cancer from getting worse. The goal was to see how well T-DM1 works in …

This study tested the safety and drug levels of risdiplam, a daily oral medication, in 174 adults and children with spinal muscular atrophy (SMA). Participants had previously received other SMA treatments. The main goals were to check for side effects and measure how the drug mov…

This completed Phase 3 trial tested a combination of two drugs, atezolizumab and bevacizumab, in 152 people with advanced liver cancer that could not be surgically removed and had not been treated before. The goal was to check safety and how well the treatment works. The study wa…

This study tested several new drug combinations in 281 people with chronic hepatitis B who were already on standard antiviral therapy. The goal was to see if adding experimental drugs could clear a key virus marker (HBsAg) from the blood. Participants received different combinati…

This early-phase study tested combinations of immunotherapy drugs (atezolizumab and tiragolumab) plus chemotherapy (carboplatin and paclitaxel) in 12 people with advanced head and neck cancer that had not been treated before. The goal was to see if these combinations could comple…

This study looked at how well MIRCERA works for anemia in people with chronic kidney disease stages 3-4 who are not yet on dialysis. Researchers tracked 144 patients over 12 months to see if their hemoglobin levels stayed in a healthy range. The goal was to gather real-world data…

This study looked at the long-term safety of the drug tocilizumab (Actemra) in 7 children with a type of arthritis called juvenile idiopathic arthritis. All children had already completed a previous study and continued to receive the drug every 4 weeks for up to 2 years. The main…

This study tested a monthly injection of Mircera in 75 adults with chronic kidney disease who were not yet on dialysis and had anemia. The goal was to see if the drug could safely raise and maintain hemoglobin levels. Results showed improvement in hemoglobin during the evaluation…

This study looked at how well the drug tocilizumab (Actemra) works for people with moderate to severe rheumatoid arthritis in everyday medical practice. Researchers followed 322 adults for 12 months after starting treatment. The main goals were to see how many patients achieved l…

This study tested whether a once-monthly injection of Mircera works as well as the standard epoetin alfa treatment for managing anemia in people on dialysis. About 233 adults with chronic kidney disease-related anemia participated. The goal was to see if Mircera could keep hemogl…

This study compares a new rapid point-of-care test for chlamydia, gonorrhea, and mycoplasma genitalium to standard lab testing. The goal is to see if the faster test helps doctors give the right antibiotics on the same day, reducing unnecessary or missed treatments. Participants …

This study looked at whether using a liquid biopsy (a blood test that detects cancer DNA) early in the diagnostic process could help doctors diagnose and recommend treatment faster for people with advanced lung or gastrointestinal cancer. 463 participants were enrolled across mul…

This study tested a drug called crovalimab in 95 people with sickle cell disease to see if it could prevent vaso-occlusive episodes (painful blockages in blood vessels). Participants received either crovalimab or a placebo alongside their usual treatments. The goal was to measure…

This study compared a single dose of baloxavir marboxil to a 5-day course of oseltamivir in 100 Chinese children aged 1 to 12 with flu symptoms. The main goal was to check safety, including side effects. Researchers also measured how quickly symptoms like cough and fever improved…

This study looked at whether people with early or locally advanced HER2-positive breast cancer prefer receiving their medication (a combination of pertuzumab and trastuzumab) at home versus in the hospital. About 346 participants were randomly assigned to receive the drug at home…

This study looked at whether people with non-small cell lung cancer prefer getting the drug atezolizumab as a shot under the skin (subcutaneous) or through an IV drip. About 179 patients tried both methods and reported which they liked better. The goal was to see if the shot is m…

This completed registry followed nearly 8,000 adults with solid tumors who had next-generation sequencing (NGS) genetic testing. The goal was to collect real-world data linking test results, treatments, and survival. No new drug or intervention was tested; instead, the registry a…

This study checked how the multiple sclerosis drug ocrelizumab passes from mother to baby during pregnancy. Researchers measured B cell levels in 70 infants whose mothers took the drug around the time of pregnancy. The goal was to see if the drug affects the baby's immune system …

This study measured the thickness of the conjunctiva and Tenon's capsule (outer eye layers) in 736 people with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME), and in healthy volunteers of similar age. Researchers used a special eye scanner (SD…

This study tested a screening platform to check tumor tissue for specific biomarkers. The goal was to see if patients with solid tumors could be eligible for a linked Roche clinical trial. About 470 participants provided tumor samples for testing. The study is now complete and fo…

This study looked at how much of the multiple sclerosis drug ocrelizumab gets into breastmilk and whether it affects babies' immune cells. Twenty-six breastfeeding mothers with MS or clinically isolated syndrome took part. Researchers measured drug levels in breastmilk and checke…